Research Center for Charged Particle Therapy Hospital, National Institute of Radiological Sciences, Chiba, Japan.
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):100-6. doi: 10.1016/j.ijrobp.2011.06.1952. Epub 2011 Nov 19.
To assess outcomes of carbon ion radiotherapy for diffuse astrocytomas in adults.
Between October 1994 and February 2002, 14 patients with diffuse astrocytoma, identified as eligible for carbon ion radiotherapy, were enrolled in a phase I/II clinical trial. Carbon ion radiotherapy was administered in 24 fractions over 6 weeks. The normal tissue morbidity was monitored carefully, and the carbon ion dose was escalated from 50.4 Gy equivalent (GyE) to 55.2 GyE. Patients were divided into two groups according to their carbon ion doses: a low-dose group in which 2 patients were irradiated with 46.2 GyE and 7 patients were irradiated with 50.4 GyE, and a high-dose group in which 5 patients were irradiated with 55.2 GyE.
Toxicities were within acceptable limits, and none of the patients developed Grade 3 or higher acute or late reactions. The median progression-free survival (PFS) time was 18 months for the low-dose group and 91 months for the high-dose group (p = 0.0030). The median overall survival (OS) time was 28 months for the low-dose group and not reached for the high-dose group (p = 0.0208).
High-dose group patients showed significant improvement in PFS and OS rates compared to those in the low-dose group, and both dose groups showed acceptable toxicity.
评估碳离子放疗治疗成人弥漫性星形细胞瘤的疗效。
1994 年 10 月至 2002 年 2 月期间，14 名符合碳离子放疗条件的弥漫性星形细胞瘤患者参加了一项 I/II 期临床试验。碳离子放疗采用 24 个分次，6 周完成。密切监测正常组织并发症，并逐步提高碳离子剂量，从 50.4Gy 等效剂量（GyE）增加至 55.2GyE。根据碳离子剂量将患者分为两组：低剂量组（2 名患者接受 46.2GyE，7 名患者接受 50.4GyE）和高剂量组（5 名患者接受 55.2GyE）。
毒性反应在可接受范围内，没有患者出现 3 级或以上的急性或迟发性反应。低剂量组的中位无进展生存期（PFS）为 18 个月，高剂量组为 91 个月（p = 0.0030）。低剂量组的中位总生存期（OS）为 28 个月，高剂量组尚未达到（p = 0.0208）。
与低剂量组相比，高剂量组患者的 PFS 和 OS 率显著提高，且两组的毒性反应均可接受。
